Literature DB >> 16272402

Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values.

Johanna Weiss1, Walter Emil Haefeli.   

Abstract

In cell culture systems with aqueous buffers, concentration-response curves to lipophilic inhibitors are difficult to establish because plateau effects (Imax) are often not reached because of limited drug solubility. Consequently, the inhibitory potency of a compound will not be definable using IC50 values (concentration exerting 50% of Imax). Since alternative potency measures f2 values, the concentrations required to double baseline signals have been proposed. Using both methods, we reevaluated the concentration-response curves of calcein assays with 78 compounds in three different cell culture systems and found a close correlation between both methods (r(s) = 0.93-0.99, p < or = 0.0028). These findings suggest that f2 values are a valuable alternative to define rank orders of highly lipophilic inhibitors as a basis for the prediction of pharmacological interaction properties in clinical settings. Although it was only tested for inhibition of P-glycoprotein, it seems likely that this method may be transferred to other assays with other proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272402     DOI: 10.1124/dmd.105.007377

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

1.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

2.  Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.

Authors:  Tanja Peters; Heike Lindenmaier; Walter E Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-20       Impact factor: 3.000

3.  Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers.

Authors:  Donald L Melchior; Frances J Sharom; Raymond Evers; George E Wright; Joseph W K Chu; Stephen E Wright; Xiaoyan Chu; Jocelyn Yabut
Journal:  J Pharmacol Toxicol Methods       Date:  2012-02-26       Impact factor: 1.950

4.  Identification of Small Molecule Inhibitors of Clostridium perfringens ε-Toxin Cytotoxicity Using a Cell-Based High-Throughput Screen.

Authors:  Michelle Lewis; Charles David Weaver; Mark S McClain
Journal:  Toxins (Basel)       Date:  2010-07-01       Impact factor: 5.075

5.  In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.

Authors:  Johanna Weiss; Evelyn Sawa; Klaus-Dieter Riedel; Walter Emil Haefeli; Gerd Mikus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-31       Impact factor: 3.000

6.  Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro.

Authors:  Johanna Weiss; Dirk Theile; Zdenek Dvorak; Walter Emil Haefeli
Journal:  Pharmaceutics       Date:  2014-12-16       Impact factor: 6.321

7.  Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.

Authors:  Johanna Weiss; Thomas Gajek; Bruno Christian Köhler; Walter Emil Haefeli
Journal:  Pharmaceutics       Date:  2016-02-24       Impact factor: 6.321

8.  Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.

Authors:  Camilla Bernasconi; Olavi Pelkonen; Tommy B Andersson; Judy Strickland; Iwona Wilk-Zasadna; David Asturiol; Thomas Cole; Roman Liska; Andrew Worth; Ursula Müller-Vieira; Lysiane Richert; Christophe Chesne; Sandra Coecke
Journal:  Toxicol In Vitro       Date:  2019-05-31       Impact factor: 3.500

9.  Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

Authors:  Jeanne Mendell; Hamim Zahir; Nobuko Matsushima; Robert Noveck; Frank Lee; Shuquan Chen; George Zhang; Minggao Shi
Journal:  Am J Cardiovasc Drugs       Date:  2013-10       Impact factor: 3.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.